Skip to main content
. 2023 Oct 7;31(12):3531–3544. doi: 10.1016/j.ymthe.2023.10.004

Table 1.

Patient characteristics

Alofisel®/darvadstrocel (n = 27) Placebo (n = 15)
Age (years) 35 42
Male 12 (44%) 6 (40%)
Female 15 (56%) 9 (60%)
Perianal Crohn’s Disease Activity Index Score 6.1 8.6
C-reactive protein (nmol/L) 8.6 11.8

Treatments

Anti-TNF 10 (37%) 8 (54%)
Immunomodulators 6 (22%) 3 (20%)
anti-TNF and immunomodulators 5 (19%) 2 (13%)
Neither 6 (22%) 2 (13%)